Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN)
following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque
320) in patients with moderate-to-severe chronic kidney disease and diabetes mellitus
undergoing cardiac angiography.